Your browser doesn't support javascript.
Low Prevalence of Interferon-α Autoantibodies in People Experiencing Long COVID Symptoms.
Peluso, Michael J; Mitchell, Anthea; Wang, Chung Yu; Takahashi, Saki; Hoh, Rebecca; Tai, Viva; Durstenfeld, Matthew S; Hsue, Priscilla Y; Kelly, J Daniel; Martin, Jeffrey N; Wilson, Michael R; Greenhouse, Bryan; Deeks, Steven G; DeRisi, Joseph L; Henrich, Timothy J.
  • Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • Mitchell A; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Wang CY; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Takahashi S; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • Hoh R; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • Tai V; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • Durstenfeld MS; Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA.
  • Hsue PY; Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA.
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Wilson MR; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
  • Greenhouse B; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, University of California,  San Francisco, San Francisco, CA, USA.
  • DeRisi JL; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Henrich TJ; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
J Infect Dis ; 2022 Sep 12.
Article in English | MEDLINE | ID: covidwho-2244144
ABSTRACT
Interferon (IFN)-specific autoantibodies have been implicated in severe COVID-19 and have been proposed as a potential driver of the persistent symptoms characterizing Long COVID, a type of post-acute sequelae of SARS-CoV-2 infection (PASC). We report than only two of 215 SARS-CoV-2 convalescent participants tested over 394 timepoints, including 121 people experiencing Long COVID symptoms, had detectable IFN-α2 antibodies. Both had been hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to Long COVID symptoms in the post-acute phase of the infection.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Infdis